Aligning our data with The Cancer Genome Atlas (TCGA) for colon and rectal cancer enabled us to identify a distinct gene signature of tumor-infiltrating myeloid cells in CRC patients that serves as an independent prognostic indicator for disease-specific survival, referred to as “the poor prognosis CD33+ gene signature”. The gene discussed is CD33; the disease is colorectal carcinoma.